Introduction: Why medicine advertising is a legal minefield in Morocco
A few years ago, a pharmacy in Casablanca launched what looked, at first glance, like a harmless Instagram campaign for an antihistamine. Clean visuals, reassuring wording, a few boosted posts, and a call to ask the pharmacist for advice. Three weeks later, a formal warning arrived. The issue was not the design. It was the law. The campaign promoted a medicinal product without going through the prior approval channel of the Direction du Médicament et de la Pharmacie (DMP). That kind of story is no longer exceptional.
Since COVID-19, pharmaceutical marketing in Morocco has changed speed. Laboratories, distributors, pharmacies and sometimes even physicians or pharmacists with large online audiences have moved into digital communication much faster than compliance teams could follow. Many professionals still have the impression that online promotion sits in a legal grey zone. In reality, the Moroccan legal framework already exists. It is not light. It is not optional. And it can be costly to ignore.
The central text is Law No. 17-04 forming the Code of Medicines and Pharmacy, promulgated by Dahir n° 1-06-151 and published in the Bulletin Officiel. This law, together with its implementing texts and the practice of the Ministry of Health and Social Protection, sets strict rules on what may be said, to whom, by whom, and only after what type of authorization. The rule that surprises many advertisers is simple: not every medicine may be advertised to the general public, and even where public advertising is theoretically allowed, prior authorization remains the cornerstone.
Concretely, the legal questions are these. Can a pharmaceutical company advertise a prescription-only medicine to the public? No. Can a pharmacist or doctor promote a product on social media just because the account is “professional”? Not freely. Does a campaign approved in one version remain valid forever? Again, no. A change in the wording, a modified visual, or an update to the marketing authorization can turn a previously lawful campaign into a non-compliant one.
This article explains the drug advertising regulation in Morocco in practical English, with the legal references that matter on the ground: the relevant provisions of Law 17-04, the role of the Ministry of Health, the place of the Ordre National des Pharmaciens, the possible intervention of the HACA for audiovisual content, and the sanctions that may follow unlawful promotion. The aim is straightforward: help laboratories, agencies, pharmacists, physicians, foreign manufacturers and compliance teams understand the encadrement juridique publicité médicale Maroc and avoid avoidable mistakes.
If you work in this sector, one practical truth should be kept in mind from the start. In theory, the review period is sixty days. In practice, if your file is incomplete, if the Arabic and French versions do not match, or if your claims go beyond the approved summary of product characteristics, you can easily lose months. That frustration is common in the market. But the legal answer remains the same: do not disseminate first and regularize later. Under Moroccan law, that approach is precisely what creates exposure.
This is therefore not just an article about rules. It is also about risk management. Because in Morocco, medicine advertising is not treated as ordinary commercial speech. It is regulated as a public health matter.
The legal foundation: Law 17-04 and the Moroccan Code of Medicines and Pharmacy
Law 17-04 and its adoption
The backbone of the publicité pharmaceutique Maroc loi is Law No. 17-04 forming the Code of Medicines and Pharmacy, promulgated by Dahir n° 1-06-151 of 22 November 2006 and published in the Bulletin Officiel n° 5480. This text reorganized a large part of the Moroccan pharmaceutical legal framework and remains the key point of entry for anyone dealing with the manufacturing, marketing, distribution and promotion of medicinal products.
The law does not treat advertising as a secondary issue. It addresses it directly through a dedicated set of provisions, especially Articles 66 to 75, which form the heart of the regime. Those articles draw the line between lawful scientific or commercial communication and prohibited public promotion. They also establish the role of the administration, notably the Ministry of Health through the DMP, in reviewing and controlling advertising materials.
The system was later complemented by implementing measures, including Decree n° 2-14-841 of 9 March 2015, which completed certain provisions of Law 17-04. In practice, companies should read the law and the administrative procedures together. The law provides the principles; the administrative practice gives them operational meaning.
Articles 66 to 75: the core advertising provisions
Article 66 is essential because it defines what counts as advertising. That matters more than many operators think. Moroccan law adopts a broad approach. Advertising is not limited to television spots or newspaper inserts. It includes, in substance, any form of canvassing, prospecting or incitement intended to promote the prescription, dispensing, sale or consumption of a medicine.
Article 66 of Law 17-04 treats as advertising for medicinal products any form of information, canvassing or inducement designed to promote prescription, dispensing, sale or consumption of those products.
That broad definition has practical consequences. A sponsored Instagram post, a radio script, a leaflet distributed in a pharmacy, a branded awareness message naming a product, or a promotional e-mail targeting consumers may all fall within the legal notion of advertising. The fact that the message claims to be educational does not automatically remove it from the scope of the law if, in reality, it encourages product consumption.
Article 67 then introduces a fundamental distinction: communication aimed at the general public is not treated the same way as communication aimed at health professionals. This distinction is central to the entire Moroccan system. A product that may be discussed within a scientific framework to physicians or pharmacists cannot necessarily be promoted to ordinary consumers.
Articles 68 to 75 set the conditions, prohibitions and control mechanisms. The most cited rule in practice is the requirement of prior authorization for advertising addressed to the public. Just as important is the absolute prohibition on public advertising for medicines subject to mandatory medical prescription.
The legal definition of “advertising” under Moroccan law
The breadth of the legal definition is what makes the code du médicament Maroc publicité regime particularly strict. A company cannot safely assume that modern digital formats fall outside a 2006 text. The wording of the law is technology-neutral enough to capture contemporary channels. If the content encourages the purchase, request or use of a medicine, the administration will generally look at the substance, not the label.
That is why social media is such a recurring source of trouble. This point is where many clients discover the problem too late. The law of 2006 does not mention Instagram, TikTok or influencer content. But inspectors are not limited by platform names. They look at whether the post amounts to pharmaceutical advertising. If it does, the classic rules apply.
Scope of application: which products are covered?
The regime primarily concerns medicinal products for human use. It also extends, depending on the circumstances and the legal classification of the product, to certain compounded preparations and related health products. The first compliance reflex should therefore always be classification. Is the product legally a medicine under Moroccan law? Is it a medical device? A cosmetic? A food supplement? The answer changes the legal regime.
That distinction is not academic. A food supplement or parapharmaceutical product is not automatically subject to the exact same rules as a medicine. But attention toutefois: if a supplement is promoted with therapeutic claims suggesting treatment, cure or prevention of disease, Moroccan authorities may reclassify the product or at least treat the communication as unlawful because it encroaches on the reserved field of medicinal claims. That is where consumer law, unfair commercial practice rules and pharmaceutical law begin to overlap.
By contrast, the package leaflet and labelling required by the marketing authorization are not, in principle, treated as advertising in the same sense, because their purpose is regulatory information rather than commercial promotion. The line, however, is thin. Once mandatory information is repackaged into promotional language, the protection disappears.
Prior authorization: the unavoidable step before any dissemination
The principle of mandatory approval
Under Article 68 of Law 17-04, advertising of medicines addressed to the general public is subject to prior authorization by the administration. In Morocco, that means the Ministry of Health and Social Protection, acting through the Direction du Médicament et de la Pharmacie. This is the cornerstone of the autorisation publicité médicament Maroc system.
Article 68 of Law 17-04: advertising directed at the public for medicinal products may only be disseminated after prior authorization from the administration.
In plain terms, the campaign must be cleared before launch. Not after publication. Not after the first week of testing. Not subject to later regularization. The legal sequence matters. A company that goes live and files later is already in breach.
The applicant is usually the laboratory, the marketing authorization holder, or the entity acting through a duly empowered local representative. For foreign laboratories without a Moroccan establishment, the practical route is to act through a local legal representative or mandate holder domiciled in Morocco. This is not just an administrative convenience. It also creates a local point of accountability vis-à-vis the authorities.
The filing procedure before the Ministry of Health
The file is submitted to the DMP. While administrative practice may evolve, the core expectation remains stable: the authority wants to review the exact content that will be disseminated. That means the final or near-final script, visuals, wording, claims and product references. If the campaign is audiovisual, the script and storyboard matter. If it is printed, the mock-up matters. If it is digital, screenshots, text, hashtags, sponsored wording and landing page references may all matter.
As a practical matter, applicants generally prepare a file including the following elements:
- A copy of the Moroccan marketing authorization (AMM) for the medicine concerned.
- The exact advertising material: mock-up, script, text, visual layout, audio or video version, depending on the support.
- A translation where needed, especially where the authority requires consistency between Arabic and French versions.
- An attestation or covering letter from the laboratory confirming the identity of the product and the conformity of the claims with the approved product information.
- Any supporting scientific or regulatory justification if the authority requests clarification on a claim.
One practical tip, learned the hard way by many operators: file the Arabic and French versions simultaneously. A monolingual file often triggers a formal objection or a request for completion, and that can effectively restart the clock. This is one of those details that looks minor until it costs a campaign launch date.
Legal timelines and real-world timelines
The editorial brief refers to a 60-day legal review period from the filing of a complete application. That timeframe is widely cited in practice and remains the benchmark used by operators planning campaigns. But let us be candid: on the ground, the effective timeline is often longer. Three to six months is not unusual, especially where the file is incomplete, the claims require clarification, or the product category is sensitive.
In theory, sixty days. In practice, often more. If the file is incomplete at first submission, count on delays. And it often is incomplete, particularly for digital campaigns where the advertiser underestimated how broadly the administration would assess the promotional ecosystem.
There is also an important practical point about administrative silence. In real compliance practice, operators do not treat silence as a green light. The prudent reading is the opposite: do not disseminate without written approval. For a regulated sector tied to public health, assuming tacit authorization is a hazardous strategy.
Advertising directed at health professionals
Communication directed exclusively to physicians, pharmacists and other health professionals is subject to a different logic. It may be more permissive than public advertising, but that does not mean it is free from control. The content must remain strictly scientific, objective and faithful to the approved product information. It should not slip into disguised consumer promotion or unlawful inducement.
For companies operating in this space, the safest internal rule is simple: classify every campaign at the outset. Is this public advertising, professional communication, disease awareness, or corporate communication? Confusion at that stage is what often creates downstream violations.
Businesses needing tailored compliance support in the capital often seek assistance from a pharmaceutical law lawyer in Rabat, especially for DMP filing strategy and document review before submission.
What the law absolutely forbids
Prescription-only medicines: no public advertising
The strongest rule appears in Article 70 of Law 17-04. It prohibits advertising to the general public for medicines that are subject to mandatory medical prescription. This is not a soft restriction. It is an absolute ban, and it sits at the center of the publicité médicament sur ordonnance Maroc regime.
Article 70 of Law 17-04: advertising to the general public is prohibited for medicinal products whose dispensing is subject to mandatory medical prescription.
This means a laboratory cannot advertise a prescription-only medicine to consumers in the press, on television, via sponsored online content, through influencers, or by pharmacy-window promotion aimed at the public. The support does not change the result. A post on social media remains advertising if it promotes a prescription-only product to ordinary users.
This is where many digital campaigns fail. A marketing team may reason that a general wellness post mentioning a product name is educational. But if the medicine is prescription-only and the post encourages interest, demand or use, the legal conclusion is usually straightforward: prohibited public advertising.
Claims must match the approved product information
Another pillar of the regime is substantive truthfulness. Under the logic of Article 71, advertising may only contain claims that are consistent with the approved Résumé des Caractéristiques du Produit (RCP), the summary of product characteristics validated during the marketing authorization process. In English, the rule is simple: you may not promise more in advertising than the AMM allows you to say scientifically and regulatorily.
That excludes a wide range of risky formulations: guaranteed cure, miracle effect, zero side effects, faster than any competitor, suitable for everyone, or medically implied uses not covered by the approved indication. The same applies to exaggeration by omission. A claim can be misleading not only because it is false, but because it suppresses the conditions, limitations or warnings attached to the approved use.
Moroccan law also intersects here with broader rules against misleading commercial practices, including the logic of Law 31-08 on consumer protection. So a company may face pharmaceutical-law exposure and consumer-law exposure at the same time if the message is deceptive.
For businesses concerned with comparative statements, brand claims or the protection of market positioning, consultation with a Moroccan intellectual property lawyer is often useful, because advertising disputes can quickly overlap with trademark, unfair competition and denigration issues.
Testimonials, guarantees and degrading comparisons
As a matter of compliant practice, advertising should avoid patient testimonials presented as proof of therapeutic certainty, guaranteed outcomes, or emotionally manipulative claims implying that failure to consume the product endangers health in a simplistic way. These techniques are particularly sensitive in the health sector because they distort informed medical judgment and exploit consumer vulnerability.
Comparative advertising is not entirely impossible in Moroccan commercial law, but in the pharmaceutical sector it is a dangerous terrain. Any comparison must be objective, verifiable and non-misleading. It must not disparage a competitor. In practice, because of the regulatory sensitivity and the scientific burden of proof, many operators choose a conservative approach.
Gifts, advantages and inducements to prescribers
The Moroccan framework also draws a red line around inducements to health professionals. The editorial brief rightly points to Article 72 as a key reference for the prohibition of benefits granted in exchange for prescriptions or dispensing behavior. This issue is not always visible in public campaigns, but it is one of the most serious compliance risks in the sector.
Cash incentives, disguised hospitality, gifts of significant value, promises tied to prescription volume, or in-kind benefits intended to influence professional judgment may trigger both regulatory and disciplinary consequences. The problem is not only criminal or administrative. It can also lead to professional-order proceedings before the relevant body.
For doctors and pharmacists, the issue is therefore not just whether the campaign is authorized under the ministère santé Maroc publicité pharmaceutique rules. It is also whether their conduct remains consistent with professional ethics. A physician who appears in a promotional campaign, or a pharmacist who amplifies a product in exchange for a benefit, may expose himself or herself on both fronts.
Mandatory mentions in authorized public advertising
Where public advertising is allowed, the content must include certain core references. In practice, compliant materials should clearly identify the international nonproprietary name (INN/DCI) of the active substance, the brand name, and a warning such as “Before use, read the leaflet carefully” or an equivalent formula approved by the authority. The key point is that the message must not mislead by over-simplifying a medicinal act into ordinary consumption.
The public-health rationale is clear. Medicines are not ordinary consumer goods. Moroccan law wants the consumer reminded of that fact in the communication itself.
Online advertising and social media: the contemporary compliance challenge
A 2006 law applied to 2020s platforms
The law does not expressly list social networks, influencer reels or sponsored health content. But because the definition of advertising is broad, the classical rules apply to digital channels. This is now reinforced in administrative practice. The Ministry of Health has, through circular guidance and compliance messaging, reminded operators that the prior authorization principle applies to all forms of medicine advertising, regardless of the medium.
That means the règles diffusion publicité médicale Maroc do not disappear online. They simply become harder to police and easier to violate. A campaign can be launched in hours, copied by affiliates, boosted by an agency, reposted by a pharmacist, and mirrored on foreign-hosted platforms before anyone in legal has seen the final wording.
Health influencers, pharmacists and physicians on social media
Can a pharmacist or physician promote a medicine on a professional social media account? As a rule, not without respecting the pharmaceutical advertising regime. The account’s professional nature does not exempt the content from the law. If the post promotes a specific medicine, encourages its consumption, or functions as a sponsored recommendation, it may be treated as pharmaceutical advertising.
This is one of the hottest risk areas today. I see more clients arrive with social-media problems than with classic print problems. The platform feels informal; the law is not. And where the person posting is a member of a regulated profession, the exposure is doubled: regulatory and disciplinary.
The Ordre National des Pharmaciens and the Ordre des Médecins may intervene from a deontological angle where a professional uses their status to promote products improperly. The fact that compensation came through an agency rather than directly from a laboratory will rarely neutralize the issue.
Cross-border digital campaigns targeting Morocco
Another difficulty concerns campaigns technically launched from abroad. Suppose a foreign laboratory runs French- or Arabic-language online ads hosted outside Morocco but targeting Moroccan users. The absence of local servers does not solve the problem if the campaign is directed at the Moroccan public and promotes products marketed in Morocco. Authorities will look at the target market and the public-health impact, not merely the place of upload.
Foreign operators entering the market would be wise to involve local counsel early, including where broader business structuring is at stake. A business lawyer in Casablanca can help align regulatory, distribution and representation arrangements before marketing begins.
Sanctions for unlawful pharmaceutical advertising
Criminal sanctions under Law 17-04
The sanctions are not symbolic. According to the editorial brief and the sanctioning framework under Article 106 of Law 17-04, unauthorized pharmaceutical advertising may lead to fines ranging from 10,000 to 100,000 Moroccan dirhams. In more serious situations, especially repeat offending or aggravated breaches, imprisonment from one month to one year may be added.
Article 106 of Law 17-04 provides for criminal penalties, including fines and possible imprisonment, for breaches of the pharmaceutical advertising rules.
For operators used to ordinary consumer advertising, this often comes as a shock. In Morocco, unlawful medicine promotion is not treated as a mere marketing irregularity. It can become a penal matter. For that reason alone, companies should never leave campaign validation solely to the commercial team.
Where criminal exposure is real, businesses and professionals may need support from a criminal lawyer in Casablanca familiar with health-sector regulatory offences.
Administrative sanctions: suspension, withdrawal, confiscation
Criminal penalties are only part of the picture. Administrative measures may be just as damaging. The authorities may order the withdrawal of the advertising material, the confiscation of supports, and, in serious cases, steps affecting the marketing authorization (AMM) itself, including suspension or withdrawal. If a campaign is built around a product whose AMM later changes, the advertising authorization may also lose its basis.
This is why companies should not think of advertising approval as indefinite. It is granted for a specific version of a specific message tied to a given regulatory status. Change the text, change the visual emphasis, change the indication, change the dosage context, or modify the AMM, and the legal foundation may disappear.
Who can be held liable?
Liability may extend beyond the laboratory. The agency that designed or disseminated the campaign, and even the media outlet or platform operator that published it without checking authorization where verification was expected, may find themselves drawn into the dispute. The exact distribution of liability will depend on the facts, contracts and knowledge of each actor, but from a risk perspective, no participant should assume immunity.
That includes pharmacists who repost, doctors who endorse, distributors who localize foreign materials, and influencers who transform a commercial brief into public-facing health promotion. In practice, Moroccan enforcement can be cumulative: administrative scrutiny, criminal complaint, unfair competition action by a rival, and professional-order proceedings may all coexist.
For misleading claims affecting consumers, support from a consumer law lawyer in Morocco may also be necessary, particularly where the issue overlaps with deceptive advertising and unfair commercial practices.
Concrete examples from Moroccan practice
Publicly accessible, fully consolidated case law on pharmaceutical advertising remains less abundant than in some European jurisdictions, but practitioners in Morocco are familiar with disputes involving unauthorized radio, print and point-of-sale promotion. The market has also seen contentious matters before the Commercial Court of Casablanca involving generic competition and disputed promotional practices. The 2019 matter often referred to by practitioners, involving a generic laboratory and unauthorized radio promotion, is regularly cited as a reminder that sanctions are not theoretical.
Even where a case does not produce a widely published precedent, the practical message is the same: complaints may come from competitors, inspectors, professional orders or broadcasters themselves. Once the file is opened, the company’s internal approval trail becomes crucial. If there is no documentary proof of prior legal validation and DMP authorization, the defence becomes much harder.
Who monitors pharmaceutical advertising in Morocco?
The Direction du Médicament et de la Pharmacie (DMP)
The DMP is the central actor. It receives and reviews authorization requests, assesses compliance, and can intervene when advertising appears unlawful. For any company asking about contrôle publicité produits pharmaceutiques Maroc, the DMP is the first institution to understand.
Its role is not merely clerical. It is substantive. The DMP examines whether the product is eligible for public promotion, whether the claims match the approved product information, whether the format is acceptable, and whether the required mentions are present. It also serves as the practical point of contact for many post-diffusion issues.
Pharmaceutical inspectors
Morocco’s pharmaceutical inspection bodies may establish violations through reports and field controls. Their intervention is particularly relevant when unlawful promotion occurs in pharmacies, medical settings, public events, or via physical promotional supports. In digital matters, screenshots and archived content can play an equivalent evidentiary role.
The professional orders
The Ordre National des Pharmaciens du Maroc may react where pharmacists are involved in improper promotion, and the Conseil National de l’Ordre des Médecins may do the same for physicians. These institutions do not replace the Ministry, but they add a disciplinary layer that can be professionally serious.
That is why a pharmacist or doctor should never assume that “everyone does it on social media” is a defence. It is not. Professional ethics in health communication remain stricter than ordinary influencer culture.
The HACA for audiovisual advertising
Where the advertisement is broadcast on radio or television, the Haute Autorité de la Communication Audiovisuelle (HACA) may also enter the picture. The relationship between HACA control and DMP authorization is practical rather than alternative. The safe route is to secure the DMP visa first, then ensure compliance with audiovisual broadcasting rules. For television and radio operators, this is particularly important, because airing a non-compliant pharmaceutical ad can expose the broadcaster as well.
Practical compliance guide: how to secure a medicine advertising campaign in Morocco
Start with the product’s legal status
Before discussing slogans, visuals or media buying, verify one thing: does the product have a valid Moroccan AMM? Without a valid marketing authorization, any medicine advertising is unlawful. Then ask the second question: is the medicine prescription-only? If the answer is yes, public advertising is off the table. The discussion should shift immediately to scientific communication and professional channels, not consumer promotion.
Prepare the DMP file carefully
Once the product is eligible for public advertising in principle, prepare the file with discipline. Gather the AMM, the RCP, the final mock-ups or scripts, the Arabic and French versions, and an internal legal memo mapping every claim to the approved product information. This is where many companies save time or lose it. A well-prepared file may move. A sloppy one returns.
As for budget, legal review and compliance support for a campaign often falls, in practice, within a range that may start around 5,000 to 15,000 MAD for focused advisory work, excluding broader litigation, translation costs, agency compliance review, or complex cross-border structuring. Translation and adaptation costs should also be anticipated from the outset.
Do not test the campaign before approval
This sounds obvious, yet it happens constantly. A teaser post, a “soft launch,” a pilot radio insert, a private boosted audience, or an influencer story published “just for engagement” before formal clearance can all create legal exposure. Under Moroccan pharmaceutical law, there is no safe informal phase for advertising that requires prior authorization.
Keep the dated filing receipt carefully. If a dispute later arises over timing, this document becomes important. But remember: the receipt proves filing, not authorization.
Respect the approved version exactly
Once authorization is granted, use the approved content and nothing else. This point is often underestimated. The authorization is attached to a specific version of the message. If marketing later changes a headline, swaps a patient image, adds a comparative phrase, shortens the warning line, or localizes the wording for a different audience segment, a new filing may be necessary.
Companies should therefore put in place an internal version-control process. Compliance teams should monitor live materials against the approved file, and regulatory teams should track any AMM change that might undermine the basis of the campaign.
Special caution for foreign laboratories
Foreign manufacturers entering Morocco should not assume that a campaign approved abroad can be imported as is. Moroccan law has its own product classification, language expectations, public-health sensitivities and administrative review process. In practice, the foreign laboratory should appoint a local representative, define contractual responsibility for compliance, and ensure that the local distributor or partner does not improvise promotional adaptations.
For businesses operating between regulatory, commercial and health-law issues, a health law lawyer in Morocco can help coordinate the strategy, while local support in major cities remains useful, including a pharmaceutical lawyer in Casablanca for contentious matters or field compliance concerns.
Conclusion: a protective framework that rewards anticipation and punishes improvisation
Moroccan law does not prohibit all medicine advertising. But it does regulate it tightly, and for good reason. The public-health stakes are high. The essential rules are clear enough once they are read properly: prior authorization is mandatory for public advertising; prescription-only medicines cannot be advertised to the general public; claims must remain strictly aligned with the approved product information; and social media is not a legal no-man’s-land.
The era in which pharmaceutical actors could treat online promotion as an informal communication exercise is over. Enforcement may still appear uneven from case to case, but the legal tools are there, the institutions exist, and complaints are increasingly easy to document. Screenshots travel fast. Competitors watch closely. Professional orders are attentive. Broadcasters and agencies are becoming more cautious.
For laboratories, pharmacies, doctors, agencies and foreign manufacturers, the practical lesson is simple: build compliance into the campaign from day one. Do not wait for a warning letter from the DMP, a complaint to the prosecutor, or a disciplinary summons from an Order. If a project touches medicine promotion in Morocco, legal review should begin before the first line of copy is approved.
And if you need tailored support on pharmaceutical regulation, health-sector compliance or contentious advertising issues, it is often worth speaking early with counsel experienced in Moroccan health law rather than trying to repair a campaign after publication.
